Log In
BCIQ
Print this Print this
 

IRT-102

  Manage Alerts
Collapse Summary General Information
Company Immune Therapeutics Inc.
DescriptionLymphocytes incubated with methionine enkephalin and low-dose naltrexone that are re-infused into a patient
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerHubei Qianjiang Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/29/2012

Undisclosed

0

0

Get a free BioCentury trial today